Gqg Partners LLC Abb Vie Inc. Transaction History

Gqg Partners LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $362,537 - $417,515	2,507 Added 5.7%	46,487 $7.41 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $59,334 - $71,158	-429 Reduced 0.97%	43,980 $7.11 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $404 Million - $463 Million	-3,007,211 Reduced 98.54%	44,409 $5.96 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $397 Million - $504 Million	2,882,655 Added 1706.07%	3,051,620 $468 Million
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $17.4 Million - $21.6 Million	131,780 Added 354.39%	168,965 $27.4 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $2.72 Million - $3.45 Million	25,358 Added 214.41%	37,185 $5.03 Million
Q3 2021 Nov 16, 2021	BUY	$106.4 - $120.78 $356,865 - $405,096	3,354 Added 39.58%	11,827 $1.28 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $327 Million - $364 Million	-3,105,796 Reduced 99.73%	8,473 $954,000
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $10.7 Million - $11.8 Million	-104,339 Reduced 3.24%	3,114,269 $337 Million
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $259 Million - $350 Million	3,218,608 New	3,218,608 $345 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Gqg Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Gqg Partners LLC with notifications on news.